Financial Data and Key Metrics Changes - Total net product revenue for Q1 2021 was approximately $124.9 million, a 24.4% increase from $100.4 million in Q1 2020 [29] - The company reported a GAAP net loss of $167.3 million for Q1 2021, compared to a net loss of $17.5 million in Q1 2020 [32] - Non-GAAP net loss for Q1 2021 was $122.5 million, compared to a non-GAAP net loss of $79.8 million in Q1 2020 [32] Business Line Data and Key Metrics Changes - Individual net product sales included $107.2 million for EXONDYS 51, $17.5 million for VYONDYS 53, and $0.2 million for AMONDYS 45 [29] - Collaboration revenue increased to $22 million in Q1 2021 from $13.2 million in Q1 2020, primarily due to the collaboration with Roche [31] Market Data and Key Metrics Changes - The company reiterated its 2021 sales guidance for the RNA franchise at $537 million to $547 million, reflecting confidence in demand despite the ongoing pandemic [30] Company Strategy and Development Direction - The company aims to expand its RNA franchise to cover a larger portion of the Duchenne community, with the potential to treat 80% or more of Duchenne patients in the U.S. [10] - The company is focused on advancing its multi-platform portfolio, including gene therapy and RNA therapies, to improve treatment outcomes for rare diseases [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of their commercial strategy, noting that they have navigated challenges posed by the COVID-19 pandemic effectively [39] - The company is optimistic about the upcoming data from clinical trials, which are expected to provide significant insights into the performance of their therapies [66] Other Important Information - The company has approximately $1.7 billion in cash, cash equivalents, and investments as of March 31, 2021, providing a strong financial position to support ongoing operations and development [37] - The company is preparing for pivotal trials and discussions with regulatory agencies regarding the next steps for its therapies [18][22] Q&A Session Summary Question: What is the status of the potency assay for Study 301? - Management confirmed that they have made significant progress on potency assays and are preparing for a meeting with the FDA to discuss the next steps [60][62] Question: What are the remaining gating factors for the initiation of Study 301? - The primary gating factors include obtaining data from Study 103 and insights from Study 102 to refine the protocol for Study 301 [66] Question: How does the company plan to approach studies for other limb girdle diseases? - The company is exploring various approaches, including potential basket trials, but will prioritize discussions with regulatory agencies to establish efficient pathways for approval [91][92]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...

Summary of Sarepta Therapeutics, Inc. Conference Call Company Overview - **Company**: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - **Event**: Cowen 41st Annual Health Care Conference - **Date**: March 3, 2021 Key Points Industry and Company Insights - **Focus on Duchenne Muscular Dystrophy (DMD)**: Sarepta is heavily invested in developing gene therapies for DMD, with significant experience in the field [4][5][6]. - **Gene Therapy Development**: The company is advancing its gene therapy programs, particularly SRP-9001, which aims to address the underlying cause of DMD by replacing the missing dystrophin protein [44][53]. Clinical Trial Updates - **Phase 2 Study 102 Results**: The company faced challenges in the Phase 2 study due to baseline imbalances among age cohorts, which affected the top-line results. The P value for baseline characteristics was reported at 0.004, indicating a significant imbalance [5][6][7]. - **Statistical Significance in Younger Cohort**: In the four to five-year-old age group, the study achieved a statistically significant result (P value of 0.017) with clinically meaningful benefits over placebo [6][7]. - **Crossover Patients**: All crossover patients have been dosed, and the study remains blinded. Data from this ongoing study is expected to provide valuable insights by the end of the year [8][9][11]. Regulatory Considerations - **FDA Approval Strategy**: The next study is anticipated to be the basis for regulatory approval, with ongoing discussions with the FDA regarding the data from the current studies [19][21][34]. - **Labeling and Market Strategy**: The company aims to create broad labeling for its therapy, ensuring that the benefits can be observed in a well-matched patient population [36][37]. Competitive Landscape - **Differentiation from Competitors**: Sarepta believes its therapy is highly differentiated in terms of safety and efficacy compared to competitors. The company has a strong proof-of-concept from its studies [25][27]. - **Market Positioning**: The company is confident in its ability to adapt its strategies based on insights gained from ongoing studies, which may inform future clinical trials [27][49]. Future Directions - **Pipeline Focus**: The company has over 40 programs but emphasizes its top priorities in DMD therapies, including AMONDYS, EXONDYS, VYONDYS, and others [51]. - **Gene Editing Initiatives**: Sarepta is exploring gene editing technologies, particularly CRISPR/Cas9, to enhance its therapeutic offerings in neuromuscular diseases [53][54]. - **Re-dosing Technologies**: The company is investigating methods to enable re-dosing of therapies, which could significantly expand treatment options for patients with pre-existing neutralizing antibodies [56][57]. Additional Considerations - **Safety Profile**: The safety profile of the therapy remains stable, with no new concerning findings reported in the crossover patients [11][12]. - **Long-term Efficacy**: There is confidence that the therapy will provide benefits across all age groups, as long as muscle tissue is present [44][45]. This summary encapsulates the critical insights and developments discussed during the conference call, highlighting Sarepta's strategic focus on DMD and its ongoing clinical and regulatory efforts.

Financial Data and Key Metrics Changes - For Q4 2020, the company achieved $122.6 million in product revenue, a 22.5% increase from the same quarter the previous year [12] - Full-year product revenue reached $455.9 million, nearly a 20% increase over the prior year [12] - The company reported a GAAP net loss of $189.3 million for Q4 2020, compared to a loss of $235.7 million in Q4 2019 [33] - Non-GAAP net loss for Q4 2020 was $145.1 million, compared to a loss of $116.9 million in Q4 2019 [34] Business Line Data and Key Metrics Changes - The RNA platform saw significant growth, with the approval of AMONDYS 45, which targets 8% of the Duchenne Muscular Dystrophy (DMD) community [13] - Collaboration revenue of $22.5 million was recognized in Q4 2020, related to a partnership with Roche [32] - Cost of sales increased to $22.4 million in Q4 2020 from $15.6 million in Q4 2019, primarily due to higher royalty payments [35] Market Data and Key Metrics Changes - The company serves approximately 30% of the DMD community with its therapies [43] - The majority of patients receiving EXONDYS 51 and VYONDYS 53 are receiving weekly infusions at home, minimizing disruptions due to the pandemic [44] Company Strategy and Development Direction - The company aims to advance its multi-platform portfolio, focusing on gene therapy, gene editing, and RNA therapeutics under the leadership of Dr. Louise Rodino-Klapac [8][26] - Plans to commence a pivotal trial for SRP-9003 in 2021, aligning with the FDA on the development path [25] - The company is committed to maintaining patient access to therapies during the pandemic and has implemented safety measures [48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by the COVID-19 pandemic but emphasized the company's commitment to serving the DMD community [11] - The company has $1.9 billion in cash as of the beginning of 2021, providing a strong foundation for reinvestment in programs [28] - Management expressed confidence in the ongoing development of therapies and the potential for significant advancements in DMD treatment [27] Other Important Information - The company plans to break out revenues for its RNA franchise in 2021, including AMONDYS 45 [32] - The ESSENCE study, a confirmatory trial for VYONDYS 53 and AMONDYS 45, is on track with expected data in 2024 [54] Q&A Session Summary Question: Insights on SRP-9001 data and limb-girdle programs - Management expressed increased confidence in the limb-girdle program based on safety and expression data from SRP-9003 [65] Question: Updates on study design and statistical analyses - Management confirmed that insights from study 102 will inform the design of the next study, aiming to increase the probability of success [70] Question: Gene editing portfolio updates - Management highlighted the establishment of a Gene Editing Innovation Center and ongoing partnerships to enhance gene editing technologies [76] Question: Enrollment confidence for upcoming studies - Management expressed confidence in rapid enrollment for study 301 due to high demand in the DMD community [81] Question: Differences between gene editing and AAV-based gene therapy - Management clarified that while gene editing is exciting, gene therapy currently offers more immediate opportunities for commercialization [86]

PART I [Item 1. Business](index=7&type=section&id=Item%201.%20Business) Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapy for rare diseases [Overview and Strategy](index=7&type=section&id=Overview%20and%20Strategy) Sarepta focuses on discovering and developing RNA-targeted therapeutics, gene therapy, and other genetic modalities for rare diseases - Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics and gene therapy for rare diseases like DMD and LGMDs[16](index=16&type=chunk) - The company's core therapeutic areas are Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs), and Charcot-Marie-tooth Disease (CMT)[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - Key strategic activities include building its gene therapy engine, advancing RNA technologies (PMO and PPMO), and investing in next-generation precision medicine through internal research and partnerships[29](index=29&type=chunk) [Commercial Products](index=9&type=section&id=Commercial%20Products) The company has three commercial products, all for the treatment of Duchenne muscular dystrophy (DMD) and all granted accelerated approval by the FDA Commercial Product Portfolio | Product | Indication | Patient Population Amenability | FDA Approval Date | | :--- | :--- | :--- | :--- | | **EXONDYS 51** | DMD amenable to exon 51 skipping | ~13% | Sep 19, 2016 | | **VYONDYS 53** | DMD amenable to exon 53 skipping | ~8% | Dec 12, 2019 | | **AMONDYS 45** | DMD amenable to exon 45 skipping | ~8% | Feb 25, 2021 | Net Product Revenue (2018-2020) | Year | Net Revenue (in millions) | | :--- | :--- | | 2020 | $455.9 | | 2019 | $380.8 | | 2018 | $301.0 | [Product Pipeline](index=9&type=section&id=Product%20Pipeline) Sarepta's pipeline includes over 40 programs, with key clinical-stage candidates for DMD and LGMD - **SRP-5051 (PPMO for DMD):** A next-generation chemistry designed for enhanced delivery and potentially less frequent dosing than PMOs for exon 51 skipping. Results from the **30 mg/kg cohort** are expected in **Q2 2021**[37](index=37&type=chunk)[38](index=38&type=chunk) - **SRP-9001 (Gene Therapy for DMD):** A micro-dystrophin gene therapy using an AAVrh.74 vector. Top-line results for Part 1 of Study 102 were released in **January 2021**, with additional results from Part 2 expected in **Q1 2022**[39](index=39&type=chunk)[40](index=40&type=chunk) - **SRP-9003 (Gene Therapy for LGMD):** A gene therapy for LGMD2E. The company expects to complete GMP runs and seek FDA confirmation to initiate a pivotal trial in **2021**[42](index=42&type=chunk)[43](index=43&type=chunk) [Manufacturing, Supply and Distribution](index=12&type=section&id=Manufacturing%2C%20Supply%20and%20Distribution) Sarepta uses a hybrid manufacturing strategy, relying on third-party CMOs for GMP production and partnering for gene therapy manufacturing - The company relies on third-party CMOs for large-scale GMP manufacturing of its commercial products and clinical candidates[46](index=46&type=chunk) - A hybrid strategy is used for gene therapy, combining internal R&D manufacturing with strategic partnerships for clinical and commercial supply[49](index=49&type=chunk) - Key gene therapy manufacturing partners include Thermo Fisher Scientific, Catalent, and Aldevron, which provide support for micro-dystrophin and LGMD programs[49](index=49&type=chunk) [Material Agreements and Strategic Alliances](index=12&type=section&id=Material%20Agreements%20and%20Strategic%20Alliances) Sarepta has key strategic agreements, including a significant collaboration with Roche for SRP-9001 and license agreements for its exon-skipping technology Roche Collaboration Financial Terms (SRP-9001) | Component | Amount | | :--- | :--- | | Up-front Payment (Cash & Equity) | ~$1.2 billion | | Potential Regulatory & Sales Milestones | Up to $1.7 billion | | Royalties on Net Sales | Mid-teens percentage | - In **2019**, Sarepta acquired Myonexus for approximately **$173.8 million** upfront to gain control of its LGMD gene therapy programs, including SRP-9003[68](index=68&type=chunk) - The company has key license agreements with BioMarin and the University of Western Australia (UWA) for its exon-skipping technology, involving milestone and royalty payments[69](index=69&type=chunk)[77](index=77&type=chunk) [Intellectual Property and Regulation](index=17&type=section&id=Intellectual%20Property%20and%20Regulation) Sarepta's success relies on patent protection and regulatory exclusivity, navigating a complex regulatory environment including FDA approval and healthcare laws U.S. Regulatory Exclusivity for Commercial Products | Product | NCE Exclusivity Until | Orphan Drug Exclusivity Until | | :--- | :--- | :--- | | **EXONDYS 51** | Sep 19, 2021 | Sep 19, 2023 | | **VYONDYS 53** | Dec 12, 2024 | Dec 12, 2026 | | **AMONDYS 45** | Feb 25, 2026 | Feb 25, 2028 | - The company's products are subject to extensive regulation by the FDA in the U.S. and other authorities abroad, covering testing, manufacturing, marketing, and distribution[105](index=105&type=chunk) - Sarepta is subject to various healthcare laws, including anti-kickback statutes and false claims laws, as well as data privacy regulations like GDPR in Europe and CCPA in California[139](index=139&type=chunk)[145](index=145&type=chunk)[146](index=146&type=chunk) [Competition and Human Capital](index=31&type=section&id=Competition%20and%20Human%20Capital) Sarepta operates in an intensely competitive biotechnology industry, particularly in the DMD space, and manages a global workforce of 866 employees - Key competitors in the DMD space include Nippon Shinyaku (**VILTEPSO**, exon 53 skipping), Pfizer (gene therapy), and Solid Biosciences (gene therapy)[160](index=160&type=chunk)[163](index=163&type=chunk)[164](index=164&type=chunk) Employee Statistics (as of Dec 31, 2020) | Metric | Value | | :--- | :--- | | Total Employees | 866 | | Research & Development | 494 | | Selling, General & Admin | 372 | | Women in Workforce | 55% | | Women in Leadership | 47% | | Racially/Ethnically Diverse | 29% | [Item 1A. Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) The company faces numerous risks, including dependence on approved DMD products, development uncertainties, manufacturing reliance, and financial challenges - **Business Risks:** The company is highly dependent on the commercial success of **EXONDYS 51**, **VYONDYS 53**, and **AMONDYS 45** in the U.S. and faces uncertainty regarding reimbursement policies and market adoption[181](index=181&type=chunk)[188](index=188&type=chunk) - **Development Risks:** Failures or delays in clinical trials, particularly for novel gene therapies, could prevent or delay regulatory approval. Results from early-stage trials may not be indicative of late-stage success[227](index=227&type=chunk)[232](index=232&type=chunk) - **Third-Party & Manufacturing Risks:** Sarepta relies on third parties for manufacturing, which creates dependence and risks related to cGMP compliance, supply chain interruptions, and the ability to scale up production for gene therapies[262](index=262&type=chunk)[269](index=269&type=chunk)[276](index=276&type=chunk) - **Operational & Financial Risks:** The **COVID-19 pandemic** may continue to disrupt commercialization, clinical trials, and manufacturing. The company has a history of operating losses and will need to raise additional funding[294](index=294&type=chunk)[307](index=307&type=chunk)[309](index=309&type=chunk) [Item 1B. Unresolved Staff Comments](index=73&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the SEC - None[351](index=351&type=chunk) [Item 2. Properties](index=73&type=section&id=Item%202.%20Properties) Sarepta's principal facilities, including corporate headquarters and laboratories, are located in Massachusetts and Ohio - The company's main facilities are located in Massachusetts and Ohio, serving as corporate headquarters, laboratory, and office space[352](index=352&type=chunk)[353](index=353&type=chunk) [Item 3. Legal Proceedings](index=73&type=section&id=Item%203.%20Legal%20Proceedings) Sarepta is involved in a patent infringement lawsuit filed by REGENXBIO INC. concerning its AAV gene therapy manufacturing technology for SRP-9001 - Sarepta is involved in a patent infringement lawsuit filed by REGENXBIO INC. related to its AAV gene therapy manufacturing technology for products like **SRP-9001**[667](index=667&type=chunk) [Item 4. Mine Safety Disclosures](index=73&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's business - Not applicable[355](index=355&type=chunk) PART II [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=74&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) Sarepta's common stock trades on the NASDAQ under symbol SRPT, with no cash dividends paid or anticipated in the foreseeable future - The company's common stock trades on the NASDAQ under the symbol **SRPT**[357](index=357&type=chunk) - No cash dividends were paid in **2018**, **2019**, or **2020**, and none are anticipated in the foreseeable future[359](index=359&type=chunk) [Item 6. Selected Financial Data](index=75&type=section&id=Item%206.%20Selected%20Financial%20Data) This section summarizes Sarepta's key financial data, showing product revenue growth but continued significant operating and net losses due to R&D investments Selected Financial Data (2018-2020) | (in thousands) | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | **Product revenues, net** | $455,865 | $380,833 | $301,034 | | **Collaboration revenue** | $84,234 | $— | $— | | **Research and development** | $722,343 | $560,909 | $401,843 | | **Operating loss** | $(564,163) | $(705,563) | $(343,628) | | **Net loss** | $(554,128) | $(715,075) | $(361,918) | | **Net loss per share** | $(7.11) | $(9.71) | $(5.46) | [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=76&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management's discussion highlights increased product and collaboration revenue, high R&D expenses, a narrowed operating loss, and boosted liquidity [Results of Operations](index=83&type=section&id=Results%20of%20Operations) Total revenues increased 42% to $540.1 million in 2020, while R&D expenses rose 29% to $722.3 million, leading to a narrowed operating loss Comparison of Operations (2020 vs. 2019) | (in thousands) | 2020 | 2019 | Change % | | :--- | :--- | :--- | :--- | | **Total revenues** | $540,099 | $380,833 | 42% | | Products, net | $455,865 | $380,833 | 20% | | Collaboration | $84,234 | $— | NM | | **Total cost and expenses** | $1,104,262 | $1,086,396 | 2% | | Research and development | $722,343 | $560,909 | 29% | | Selling, general and administrative | $317,875 | $284,812 | 12% | | **Operating loss** | $(564,163) | $(705,563) | (20)% | | **Net loss** | $(554,128) | $(715,075) | (23)% | - R&D expenses increased by **$161.4 million (29%)**, primarily driven by a **$223.9 million** increase in manufacturing expenses for the micro-dystrophin and other gene therapy programs. This was partially offset by a **$65.9 million** reimbursement from Roche[405](index=405&type=chunk)[406](index=406&type=chunk) [Liquidity and Capital Resources](index=87&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2020, Sarepta's cash, cash equivalents, and investments increased 72% to $1.95 billion, primarily due to the Roche collaboration Financial Condition Summary (as of Dec 31) | (in thousands) | 2020 | 2019 | | :--- | :--- | :--- | | **Cash, cash equivalents and investments** | $1,947,886 | $1,134,314 | | **Total borrowings** | $992,493 | $681,900 | | **Working capital** | $2,069,170 | $1,204,146 | Cash Flow Summary (Year Ended Dec 31) | (in thousands) | 2020 | 2019 | | :--- | :--- | :--- | | **Cash from Operating Activities** | $107,466 | $(456,463) | | **Cash (used in) from Investing Activities** | $(121,721) | $286,725 | | **Cash from Financing Activities** | $682,323 | $642,554 | - The company has potential future milestone obligations of up to **$3.9 billion** related to its collaboration and license agreements, which are not recorded on the balance sheet as they are contingent on future events[427](index=427&type=chunk) [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=90&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate fluctuations on its $1.95 billion investment portfolio - The company's main market risk is interest rate risk on its **$1.95 billion** portfolio of cash, cash equivalents, and investments[430](index=430&type=chunk) - A hypothetical adverse **10 basis point** change in interest rates is estimated to result in a **$0.2 million** loss in the fair value of its investments[430](index=430&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=90&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section incorporates by reference the company's consolidated financial statements and the independent auditor's report from Part IV, Item 15 - The required financial statements are located starting on page **F-1** of the report[431](index=431&type=chunk) [Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=90&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None[432](index=432&type=chunk) [Item 9A. Controls and Procedures](index=90&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2020, a conclusion confirmed by KPMG LLP - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of **December 31, 2020**[433](index=433&type=chunk) - Management concluded that internal control over financial reporting was effective as of **December 31, 2020**, an assessment audited and confirmed by **KPMG LLP**[437](index=437&type=chunk) [Item 9B. Other Information](index=91&type=section&id=Item%209B.%20Other%20Information) The company reports no other information for this item - None[439](index=439&type=chunk) PART III [Item 10. Directors, Executive Officers and Corporate Governance](index=92&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) Information regarding directors, executive officers, and corporate governance is incorporated by reference from the 2021 proxy statement - Information is incorporated by reference from the **2021 proxy statement**[440](index=440&type=chunk) [Item 11. Executive Compensation](index=92&type=section&id=Item%2011.%20Executive%20Compensation) Information regarding executive compensation is incorporated by reference from the 2021 proxy statement - Information is incorporated by reference from the **2021 proxy statement**[441](index=441&type=chunk) [Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=92&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information regarding security ownership is incorporated by reference from the 2021 proxy statement - Information is incorporated by reference from the **2021 proxy statement**[442](index=442&type=chunk) [Item 13. Certain Relationships and Related Transactions, and Director Independence](index=92&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information regarding related transactions and director independence is incorporated by reference from the 2021 proxy statement - Information is incorporated by reference from the **2021 proxy statement**[443](index=443&type=chunk) [Item 14. Principal Accounting Fees and Services](index=92&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) Information regarding principal accounting fees and services is incorporated by reference from the 2021 proxy statement - Information is incorporated by reference from the **2021 proxy statement**[444](index=444&type=chunk) PART IV [Item 15. Exhibits, Financial Statement Schedules](index=93&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists the documents filed as part of the Annual Report on Form 10-K, including consolidated financial statements and a detailed list of exhibits - This item contains the list of financial statements and exhibits filed with the **10-K**[446](index=446&type=chunk)[448](index=448&type=chunk) [Item 16. Form 10-K Summary](index=100&type=section&id=Item%2016.%20Form%2010-K%20Summary) This item is not applicable - Not applicable[457](index=457&type=chunk)

Our mission continues. KAI Living with Duchenne muscular dystrophy J.P. MORGAN HEALTHCARE CONFERENCE – JANUARY 2021 ©SAREPTA THERAPEUTICS, INC. 2021. ALL RIGHTS RESERVED. 1 Armed with the most advanced science in genetic medicine, we are in a daily race to rescue lives otherwise stolen by rare disease. At Sarepta, every day is another twenty-four hours to stand up for patients, advance technology, challenge convention, and drag tomorrow into today. DOUGLAS INGRAM President and Chief Executive Officer JP Mor ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) 39th Annual JPMorgan Virtual Healthcare Conference January 11, 2021 10:00 AM ET Company Participants Doug Ingram - CEO Gilmore O'Neill - Head of R&D Louise Rodino-Klapac - Chief Scientific Officer Dallan Murray - Chief Commercial Officer Ian Estepan - CFO Conference Call Participants Anupam Rama - JPMorgan Tessa Romero - JPMorgan Anupam Rama Welcome everyone to the 39th Annual J.P. Morgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech a ...

| --- | --- | --- | --- | |-------------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------| | | | | | | | | | | | | Clinical Update: MOMENTUM MultipleAscending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy | | | | | | | | | DOUG INGRAM | GILMORE O'NEILL , MB, MMSC | | | | President and CEO | Executive Vice President, R&D and Chief Medical Officer | | | | December ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference Call December 7, 2020 8:30 AM ET Company Participants Doug Ingram - President and Chief Executive Officer Gilmore O’Neill - Executive Vice President, R&D Conference Call Participants Salveen Richter - Goldman Sachs Tazeen Ahmad - Bank of America Gena Wang - Barclays Alethia Young - Cantor Brian Skorney - Baird Anupam Rama - JPMorgan Matthew Harrison - Morgan Stanley Tyler Va ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Evercore ISI HealthCONx Conference December 2, 2020 3:30 PM ET Company Participants Douglas Ingram - President, CEO & Director Conference Call Participants Maneka Mirchandaney - Evercore ISI Maneka Mirchandaney Great. Good afternoon, everyone. I'm Maneka Mirchandaney from the Evercore ISI biotech team. I am really pleased to be here with Sarepta. We've got Doug Ingram, who's its President and CEO; and Ian Esteban, who's SVP, Chief of Staff and Corporate Affairs. Than ...